Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Medical Genetics

The Biology of GD1 and Understanding Your Diagnosis

At a Glance

Gaucher disease type 1 (GD1) is a genetic condition caused by GBA1 gene mutations that lead to a lack of the GCase enzyme. This causes fat to build up in cells. It is diagnosed through enzyme activity assays and genetic testing, and tracked using blood biomarkers like Lyso-Gb1.

Understanding the biology of GD1 can help you feel more in control of your diagnosis. At its core, GD1 is a “recycling” problem within your cells [1][2]. Your body is made of trillions of cells, and each cell has a “recycling center” called a lysosome. In GD1, a specific “recycling tool” (an enzyme) is missing or broken, causing cellular waste to pile up [2][3].

The Chain Reaction: Genes, Enzymes, and Cells

  1. The GBA1 Gene: Everyone has two copies of the GBA1 gene, which provide the instructions for making an enzyme called β-glucocerebrosidase (GCase). In GD1, both copies of this gene have mutations [4][1].
  2. Enzyme Deficiency: Because the instructions are faulty, your body doesn’t produce enough working GCase enzyme [4][5].
  3. Substrate Buildup: Without enough GCase, a fatty substance called glucosylceramide cannot be broken down. It begins to accumulate inside specialized immune cells called macrophages [2][6].
  4. The Gaucher Cell: These macrophages become so “stuffed” with undigested fat that they change shape and appearance. Doctors call these enlarged cells Gaucher cells [4][7]. These cells then migrate to the spleen, liver, and bone marrow [4][6][8].

Confirming the Diagnosis

To confirm you have GD1, your medical team uses two primary types of tests:

  • Enzyme Activity Assay (The Gold Standard): This measures how well your GCase enzyme is working. In people with Gaucher disease, this activity is significantly lower than normal (usually less than 15% of normal) [3][9].
  • Genetic Testing: This identifies the specific mutations in your GBA1 gene [3][10].

The Role of Genotype: The N370S Mutation

Your genotype is the specific combination of mutations you inherited. In Western and Ashkenazi Jewish populations, the most common mutation is N370S [11][12]. Research shows that having at least one N370S mutation is generally associated with the non-neuronopathic (Type 1) form of the disease [12][13].

Monitoring with Biomarkers

Once you are diagnosed, doctors use “biomarkers”—substances in your blood—to see how well treatment is working.

  • Lyso-Gb1 (Glucosylsphingosine): This is the most sensitive and specific marker for Gaucher disease [14][15]. If your treatment is working, your Lyso-Gb1 levels should drop significantly [16][17].
  • Chitotriosidase: This is an enzyme produced by the Gaucher cells themselves. High levels indicate a heavy “burden” of Gaucher cells [18][19].
    • Important Caveat: Approximately 6% of the general population has a natural genetic mutation causing total chitotriosidase deficiency. For these individuals, this test will always return a zero or undetectable reading. This does not mean you have zero disease burden; your doctor will simply rely on Lyso-Gb1 or other markers like CCL18/PARC instead.

Completeness Checklist for Your Lab Reports

  • [ ] GCase Enzyme Activity: Should include your result and the lab’s “normal range.”
  • [ ] GBA1 Genetic Mutation Report: Lists your two specific mutations (e.g., N370S/N370S or N370S/L444P).
  • [ ] Baseline Lyso-Gb1 Level: Your “starting number” before beginning any therapy [15].
  • [ ] Baseline Chitotriosidase Level: Another key number for tracking your long-term progress [20].

Common questions in this guide

What causes Gaucher disease type 1?
GD1 is caused by mutations in the GBA1 gene, which are inherited. These mutations mean your body does not produce enough of the GCase enzyme needed to break down certain fatty cellular waste.
What are Gaucher cells?
Gaucher cells are immune cells, called macrophages, that have become engorged with undigested fat due to a lack of the GCase enzyme. These enlarged cells can accumulate in your spleen, liver, and bone marrow.
How do doctors diagnose GD1?
Doctors primarily diagnose GD1 using an enzyme activity assay to measure how well your GCase enzyme is working. They will also use genetic testing to identify the specific mutations in your GBA1 gene.
What does the N370S mutation mean for my prognosis?
The N370S mutation is the most common genetic change associated with GD1, particularly in Western and Ashkenazi Jewish populations. Having at least one copy of this mutation typically indicates the non-neuronopathic form of the disease.
What is Lyso-Gb1 and why do doctors monitor it?
Lyso-Gb1 is a highly sensitive biomarker found in your blood that helps doctors track Gaucher disease activity. By monitoring your Lyso-Gb1 levels over time, your medical team can determine how well your treatment is working.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you walk me through my genetic report and explain what my specific combination of GBA1 mutations means for my prognosis?
  2. 2.What was my baseline GCase enzyme activity level compared to the normal reference range?
  3. 3.Am I one of the individuals who naturally lacks chitotriosidase, and if so, how will we adjust my monitoring?
  4. 4.Now that we have my baseline Lyso-Gb1, how much of a decrease do we want to see in the first six months of treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Early Diagnosis of Gaucher Disease and ASMD in Sardinia: The "Ichnos" Project.

    Costa A, Perra D, Mulas O, et al.

    Mediterranean journal of hematology and infectious diseases 2026; (18(1)):e2026016 doi:10.4084/MJHID.2026.016.

    PMID: 41641395
  2. 2

    Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.

    Bennett LL, Turcotte K

    Drug design, development and therapy 2015; (9()):4639-47 doi:10.2147/DDDT.S77760.

    PMID: 26345314
  3. 3

    Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?

    Dinur T, Bauer P, Beetz C, et al.

    International journal of molecular sciences 2022; (23(3)) doi:10.3390/ijms23031627.

    PMID: 35163551
  4. 4

    Gaucher Disease: Clinical, Biological and Therapeutic Aspects.

    Dandana A, Ben Khelifa S, Chahed H, et al.

    Pathobiology : journal of immunopathology, molecular and cellular biology 2016; (83(1)):13-23 doi:10.1159/000440865.

    PMID: 26588331
  5. 5

    Non-neuronopathic Gaucher disease (Type I) in an elderly female: a case report.

    Bohara S, Bhattarai S, Khadka M, et al.

    Annals of medicine and surgery (2012) 2024; (86(11)):6780-6783 doi:10.1097/MS9.0000000000002566.

    PMID: 39525705
  6. 6

    Acid sphingomyelinase deficiency and Gaucher disease in adults: Similarities and differences in two macrophage storage disorders.

    Eskes ECB, van Dussen L, Aerts JMFG, et al.

    JIMD reports 2024; (65(5)):330-340 doi:10.1002/jmd2.12420.

    PMID: 39544689
  7. 7

    Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1.

    Markuszewska-Kuczynska A, Klimkowska M, Regenthal S, et al.

    Folia histochemica et cytobiologica 2015; (53(1)):62-9 doi:10.5603/FHC.a2015.0003.

    PMID: 25736845
  8. 8

    [Gaucher Disease type 1 mimicking immune thrombocytopenia: Role of hyperferritinemia and hypergammaglobulinemia in the initial evaluation of an isolated thrombopenia].

    Faucher B, Seguier J, Swiader L, et al.

    La Revue de medecine interne 2019; (40(10)):680-683 doi:10.1016/j.revmed.2019.05.013.

    PMID: 31213336
  9. 9

    Evaluation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism.

    Hertz E, Rytel K, Perez G, et al.

    Movement disorders : official journal of the Movement Disorder Society 2025; (40(8)):1719-1724 doi:10.1002/mds.30273.

    PMID: 40568761
  10. 10

    Diagnosis and genetic analysis of Gaucher disease in a pediatric case: a case report.

    Ma M, Wu N, Feng J, et al.

    Frontiers in pediatrics 2025; (13()):1628525 doi:10.3389/fped.2025.1628525.

    PMID: 40791806
  11. 11

    Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease.

    Bonesteele G, Gargus JJ, Curtin E, et al.

    Molecular genetics and metabolism reports 2020; (25()):100663 doi:10.1016/j.ymgmr.2020.100663.

    PMID: 33101982
  12. 12

    Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease.

    Lipiński P, Rokicki D, Chwiałkowska K, et al.

    Life (Basel, Switzerland) 2026; (16(3)) doi:10.3390/life16030485.

    PMID: 41901003
  13. 13

    Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report.

    Vujosevic S, Medenica S, Vujicic V, et al.

    World journal of clinical cases 2019; (7(12)):1475-1482 doi:10.12998/wjcc.v7.i12.1475.

    PMID: 31363476
  14. 14

    Glucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease.

    Carubbi F, Linari S, Spada M

    International journal of molecular sciences 2026; (27(4)) doi:10.3390/ijms27041705.

    PMID: 41751844
  15. 15

    Comprehensive and long-term outcomes of enzyme replacement therapy followed by stem cell transplantation in children with Gaucher disease type 1 and 3.

    Anurathapan U, Tim-Aroon T, Zhang W, et al.

    Pediatric blood & cancer 2023; (70(3)):e30149 doi:10.1002/pbc.30149.

    PMID: 36562549
  16. 16

    Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy.

    Dubiela P, Szymanska-Rozek P, Hasinski P, et al.

    Biomolecules 2024; (14(7)) doi:10.3390/biom14070842.

    PMID: 39062556
  17. 17

    Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.

    Cozma C, Cullufi P, Kramp G, et al.

    International journal of molecular sciences 2020; (21(13)) doi:10.3390/ijms21134577.

    PMID: 32605119
  18. 18

    Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease.

    Gayed MM, Jung SH, Huggins E, et al.

    International journal of molecular sciences 2022; (23(23)) doi:10.3390/ijms232314938.

    PMID: 36499264
  19. 19

    Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease.

    Murugesan V, Liu J, Yang R, et al.

    Blood cells, molecules & diseases 2018; (68()):47-53 doi:10.1016/j.bcmd.2016.12.002.

    PMID: 28003098
  20. 20

    An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan.

    Ida H, Watanabe Y, Sagara R, et al.

    Orphanet journal of rare diseases 2022; (17(1)):401 doi:10.1186/s13023-022-02549-6.

    PMID: 36329499

This page provides educational information about Gaucher disease type 1 biology and diagnosis. Always consult your medical team to interpret your specific genetic, enzyme, and biomarker lab results.

Get notified when new evidence is published on Gaucher disease type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.